Top

Published in:

Open Access 01-10-2020 | Stroke | Review Article

Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs

Authors: N. R. Fuggle, C. Cooper, N. C. Harvey, N. Al-Daghri, M.-L. Brandi, O. Bruyere, A. Cano, E. M. Dennison, A. Diez-Perez, J.-M. Kaufman, S. Palacios, D. Prieto-Alhambra, S. Rozenberg, T. Thomas, F. Tremollieres, R. Rizzoli, J. A. Kanis, J. Y. Reginster

Published in: Drugs | Issue 15/2020

Abstract

The incidence of osteoporosis and cardiovascular disease increases with age, and there are potentially shared mechanistic associations between the two conditions. It is therefore highly relevant to understand the cardiovascular implications of osteoporosis medications. These are presented in this narrative review. Calcium supplementation could theoretically cause atheroma formation via calcium deposition, and in one study was found to be associated with myocardial infarction, but this has not been replicated. Vitamin D supplementation has been extensively investigated for cardiac benefit, but no consistent effect has been found. Despite findings in the early 21st century that menopausal hormone therapy was associated with coronary artery disease and venous thromboembolism (VTE), this therapy is now thought to be potentially safe (from a cardiac perspective) if started within the first 10 years of the menopause. Selective estrogen receptor modulators (SERMs) are associated with increased risk of VTE and may be related to fatal strokes (a subset of total strokes). Bisphosphonates could theoretically provide protection against atheroma. However, data from randomised trials and observational studies have neither robustly supported this nor consistently demonstrated the potential association with atrial fibrillation. Denosumab does not appear to be associated with cardiovascular disease and, although parathyroid hormone analogues are associated with palpitations and dizziness, no association with a defined cardiovascular pathology has been demonstrated. Finally, romosozumab has been shown to have a possible cardiovascular signal, and therefore post-market surveillance of this therapy will be vital.

Xia W, Cooper C, Li M, et al. East meets West: current practices and policies in the management of musculoskeletal aging. Aging Clin Exp Res. 2019;31(10):1351–73. https://doi.org/10.1007/s40520-019-01282-8.CrossRefPubMedPubMedCentral

Chandran M, Tay D, Mithal A. Supplemental calcium intake in the aging individual: implications on skeletal and cardiovascular health. Aging Clin Exp Res. 2019;31(6):765–81. https://doi.org/10.1007/s40520-019-01150-5.CrossRefPubMed

Prince RL, Devine A, Dhaliwal SS, et al. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med. 2006;166(8):869–75. https://doi.org/10.1001/archinte.166.8.869.CrossRefPubMed

Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ. 2008;336(7638):262–6. https://doi.org/10.1136/bmj.39440.525752.BE.CrossRefPubMedPubMedCentral

Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation. 2007;115(7):846–54. https://doi.org/10.1161/circulationaha.106.673491.CrossRefPubMed

Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691. https://doi.org/10.1136/bmj.c3691.CrossRefPubMedPubMedCentral

Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040. https://doi.org/10.1136/bmj.d2040.CrossRefPubMedPubMedCentral

Harvey NC, Biver E, Kaufman JM et al. (2017) The role of calcium supplementation in healthy musculoskeletal ageing: an expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). 28 (2):447-462. https://doi.org/10.1007/s00198-016-3773-6.

Prentice RL, Pettinger MB, Jackson RD, et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporos Int. 2013;24(2):567–80. https://doi.org/10.1007/s00198-012-2224-2.CrossRefPubMed

10.

Cauley JA, Chlebowski RT, Wactawski-Wende J, et al. Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women’s Health Initiative. J Women’s Health (2002). 2013;22(11):915–29. https://doi.org/10.1089/jwh.2013.4270.CrossRef

11.

Lewis JR, Radavelli-Bagatini S, Rejnmark L, et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res. 2015;30(1):165–75. https://doi.org/10.1002/jbmr.2311.CrossRefPubMed

12.

Harvey NC, D’Angelo S, Paccou J, et al. Calcium and vitamin D supplementation are not associated with risk of incident ischemic cardiac events or death: findings from the UK Biobank Cohort. J Bone Miner Res. 2018;33(5):803–11. https://doi.org/10.1002/jbmr.3375.CrossRefPubMedPubMedCentral

13.

Manson JE, Allison MA, Carr JJ, et al. Calcium/vitamin D supplementation and coronary artery calcification in the Women’s Health Initiative. Menopause. 2010;17(4):683–91. https://doi.org/10.1097/gme.0b013e3181d683b5.CrossRefPubMedPubMedCentral

14.

Yang C, Shi X, Xia H, et al. The evidence and controversy between dietary calcium intake and calcium supplementation and the risk of cardiovascular disease: a systematic review and meta-analysis of cohort studies and randomized controlled trials. J Am Coll Nutr. 2019. https://doi.org/10.1080/07315724.2019.1649219.CrossRefPubMed

15.

Heaney RP, Kopecky S, Maki KC, et al. A review of calcium supplements and cardiovascular disease risk. Adv Nutr. 2012;3(6):763–71. https://doi.org/10.3945/an.112.002899.CrossRefPubMedPubMedCentral

16.

Cormick G, Ciapponi A, Cafferata ML, et al. Calcium supplementation for prevention of primary hypertension. Cochrane Database Syst Rev. 2015. https://doi.org/10.1002/14651858.cd010037.pub2.CrossRefPubMedPubMedCentral

17.

Reid IR. Effects of calcium supplementation on circulating lipids: potential pharmacoeconomic implications. Drugs Aging. 2004;21(1):7–17. https://doi.org/10.2165/00002512-200421010-00002.CrossRefPubMed

18.

Goltzman D, Mannstadt M, Marcocci C. Physiology of the calcium-parathyroid hormone-vitamin D axis. Front Horm Res. 2018;50:1–13. https://doi.org/10.1159/000486060.CrossRefPubMed

19.

Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44. https://doi.org/10.1007/s00198-018-4704-5.CrossRefPubMed

20.

Pepe J, Cipriani C, Sonato C, et al. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol. 2017;177(6):R297–308. https://doi.org/10.1530/EJE-17-0485.CrossRefPubMed

21.

Bjerregaard P, Nallapaneni H, Gussak I. Short QT interval in clinical practice. J Electrocardiol. 2010;43(5):390–5. https://doi.org/10.1016/j.jelectrocard.2010.06.004.CrossRefPubMed

22.

Durup D, Jørgensen HL, Christensen J, et al. A reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality: the CopD study. J Clin Endocrinol Metab. 2015;100(6):2339–46. https://doi.org/10.1210/jc.2014-4551.CrossRefPubMed

23.

Ellam T, Hameed A, ul Haque R, et al. Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice. PLoS One. 2014;9(2):e88767. https://doi.org/10.1371/journal.pone.0088767.CrossRefPubMedPubMedCentral

24.

Billington EO, Burt LA, Rose MS, et al. Safety of high-dose vitamin D supplementation: secondary analysis of a randomized controlled trial. J Clin Endocrinol Metab. 2019. https://doi.org/10.1210/clinem/dgz212.CrossRef

25.

Bouillon R. Vitamin D and cardiovascular disorders. Osteoporos Int. 2019;30(11):2167–81. https://doi.org/10.1007/s00198-019-05098-0.CrossRefPubMed

26.

Swart KM, Lips P, Brouwer IA, et al. Effects of vitamin D supplementation on markers for cardiovascular disease and type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. AM J Clin Nutr. 2018;107(6):1043–53. https://doi.org/10.1093/ajcn/nqy078.CrossRefPubMedPubMedCentral

27.

Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33–44. https://doi.org/10.1056/NEJMoa1809944.CrossRefPubMed

28.

Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment Study: a randomized clinical trial. JAMA Cardiol. 2017;2(6):608–16. https://doi.org/10.1001/jamacardio.2017.0175.CrossRefPubMedPubMedCentral

29.

Barbarawi M, Kheiri B, Zayed Y, et al. Vitamin D supplementation and cardiovascular disease risks in more than 83 000 individuals in 21 randomized clinical trials: a meta-analysis. JAMA Cardiol. 2019;4(8):765–75. https://doi.org/10.1001/jamacardio.2019.1870.CrossRefPubMedPubMedCentral

30.

Kanis JA, Cooper C, Rizzoli R, et al. Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clin Exp Res. 2019;31(1):15–7. https://doi.org/10.1007/s40520-018-1109-4.CrossRefPubMed

31.

Grübler MR, März W, Pilz S, et al. Vitamin-D concentrations, cardiovascular risk and events—a review of epidemiological evidence. Rev Endocr Metab Disord. 2017;18(2):259–72. https://doi.org/10.1007/s11154-017-9417-0.CrossRefPubMed

32.

Zhu L, Jiang X, Sun Y, et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2016;23(4):461–70. https://doi.org/10.1097/gme.0000000000000519.CrossRefPubMed

33.

Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85(4):447–52. https://doi.org/10.7326/0003-4819-85-4-447.CrossRefPubMed

34.

Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause (New York, NY). 2009;16(1):15–23. https://doi.org/10.1097/gme.0b013e31818888f7.CrossRef

35.

Lisabeth LD, Beiser AS, Brown DL, et al. Age at natural menopause and risk of ischemic stroke: the Framingham Heart Study. Stroke. 2009;40(4):1044–9. https://doi.org/10.1161/STROKEAHA.108.542993.CrossRefPubMedPubMedCentral

36.

Bassuk SS, Manson JE. The Timing Hypothesis: do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metab Clin Exp. 2016;65(5):794–803. https://doi.org/10.1016/j.metabol.2016.01.004.CrossRefPubMedPubMedCentral

37.

Chester RC, Kling JM, Manson JE. What the Women’s Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol. 2018;41(2):247–52. https://doi.org/10.1002/clc.22891.CrossRefPubMedPubMedCentral

38.

Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (Cambridge, Mass). 2008;19(6):766–79. https://doi.org/10.1097/EDE.0b013e3181875e61.CrossRef

39.

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. https://doi.org/10.1093/ajcn/nqy078.CrossRef

40.

Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291(1):47–53. https://doi.org/10.1001/jama.291.1.47.CrossRefPubMed

41.

Simon JA. What’s new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Clim J Int Menopause Soc. 2012;15(Suppl 1):3–10. https://doi.org/10.3109/13697137.2012.669332.CrossRef

42.

Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573–80. https://doi.org/10.1001/jama.292.13.1573.CrossRefPubMed

43.

Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA. 2003;289(20):2673–84. https://doi.org/10.1001/jama.289.20.2673.CrossRefPubMed

44.

Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523–34. https://doi.org/10.1056/NEJMoa030808.CrossRefPubMed

45.

Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166(7):772–80. https://doi.org/10.1001/archinte.166.7.772.CrossRefPubMed

46.

Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women’s Health Initiative. Circulation. 2006;113(20):2425–34. https://doi.org/10.1161/CIRCULATIONAHA.105.594077.CrossRefPubMed

47.

Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–77. https://doi.org/10.1001/jama.297.13.1465.CrossRefPubMed

48.

Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7 Suppl 1):s1–66. https://doi.org/10.1210/jc.2009-2509.CrossRefPubMedPubMedCentral

49.

Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53(3):605–19. https://doi.org/10.1016/s0008-6363(01)00466-7.CrossRefPubMed

50.

Hodis HN, Collins P, Mack WJ, et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Clim J Int Menopause Soc. 2012;15(3):217–28. https://doi.org/10.3109/13697137.2012.656401.CrossRef

51.

Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249–60. https://doi.org/10.7326/M14-0353.CrossRefPubMed

52.

Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–31. https://doi.org/10.1056/NEJMoa1505241.CrossRefPubMedPubMedCentral

53.

Baber RJ, Panay N, Fenton A, et al. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Clim J Int Menopause Soc. 2016;19(2):109–50. https://doi.org/10.3109/13697137.2015.1129166.CrossRef

54.

Canonico M, Scarabin PY. Oral versus transdermal estrogens and venous thromboembolism in postmenopausal women: what is new since 2003? Menopause. 2016;23(6):587–8. https://doi.org/10.1097/gme.0000000000000665.CrossRefPubMed

55.

Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. https://doi.org/10.1136/bmj.k4810.CrossRefPubMedPubMedCentral

56.

Sturdee DW, Pines A, International Menopause Society Writing G, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Clim J Int Menopause Soc. 2011;14(3):302–20. https://doi.org/10.3109/13697137.2011.570590.CrossRef

57.

Manson JE, Kaunitz AM. Menopause management–getting clinical care back on track. N Engl J Med. 2016;374(9):803–6. https://doi.org/10.1056/NEJMp1514242.CrossRefPubMed

58.

Yates J, Barrett-Connor E, Barlas S, et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol. 2004;103(3):440–6. https://doi.org/10.1097/01.aog.0000114986.14806.37.CrossRefPubMed

59.

Menopause: diagnosis and management; NG23. National Institute for Health and Care Excellence, London. 2015.

60.

Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697–708. https://doi.org/10.1056/NEJMoa0800743.CrossRefPubMedPubMedCentral

61.

Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279(18):1445–51. https://doi.org/10.1001/jama.279.18.1445.CrossRefPubMed

62.

Gol M, Akan P, Dogan E, et al. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas. 2006;53(3):252–9. https://doi.org/10.1016/j.maturitas.2005.05.006.CrossRefPubMed

63.

Nanetti L, Camilletti A, Francucci CM, et al. Role of raloxifene on platelet metabolism and plasma lipids. Eur J Clin Invest. 2008;38(2):117–25. https://doi.org/10.1111/j.1365-2362.2007.01905.x.CrossRefPubMed

64.

Grover-Páez F, Zavalza-Gómez AB, Anaya-Prado R. Raloxifene modifies the insulin sensitivity and lipid profile of postmenopausal insulin resistant women. Gynecol Endocrinol. 2013;29(7):674–7. https://doi.org/10.3109/09513590.2013.788628.CrossRefPubMed

65.

Colacurci N, Manzella D, Fornaro F, et al. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab. 2003;88(5):2135–40. https://doi.org/10.1210/jc.2002-021557.CrossRefPubMed

66.

Cagnacci A, Zanni AL, Volpe A. Administration of raloxifene does not influence 24-hour ambulatory blood pressure of postmenopausal women with osteopenia: a double-blind placebo-controlled study. Am J Obstet Gynecol. 2003;188(5):1278–82. https://doi.org/10.1067/mob.2003.299.CrossRefPubMed

67.

Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost. 2008;99(2):338–42.CrossRef

68.

Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686–96. https://doi.org/10.1056/NEJMoa0808692.CrossRefPubMed

69.

Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287(7):847–57. https://doi.org/10.1001/jama.287.7.847.CrossRefPubMed

70.

Ensrud K, Genazzani AR, Geiger MJ, et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol. 2006;97(4):520–7. https://doi.org/10.1016/j.amjcard.2005.09.083.CrossRefPubMed

71.

Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–37. https://doi.org/10.1056/NEJMoa062462.CrossRefPubMed

72.

Ensrud K, LaCroix A, Thompson JR, et al. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation. 2010;122(17):1716–24. https://doi.org/10.1161/CIRCULATIONAHA.109.924571.CrossRefPubMed

73.

McFarlane SI, Muniyappa R, Shin JJ, et al. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine. 2004;23(1):1–10. https://doi.org/10.1385/ENDO:23:1:01.CrossRefPubMed

74.

Bevilacqua M, Dominguez LJ, Rosini S, et al. Bisphosphonates and atherosclerosis: why? Lupus. 2005;14(9):773–9. https://doi.org/10.1191/0961203305lu2219oa.CrossRefPubMed

75.

Wagner WD, Clarkson TB, Foster J. Contrasting effects of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on the regression of two types of dietary-induced atherosclerosis. Atherosclerosis. 1977;27(4):419–35. https://doi.org/10.1016/0021-9150(77)90161-7.CrossRefPubMed

76.

Kramsch DM, Aspen AJ, Rozler LJ. Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science (New York, NY). 1981;213(4515):1511–2. https://doi.org/10.1126/science.6792706.CrossRef

77.

Gonnelli S, Caffarelli C, Tanzilli L, et al. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone. 2014;61:27–32. https://doi.org/10.1016/j.bone.2013.12.017.CrossRefPubMed

78.

Yang Y, Rong X, Lv X, et al. Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway. Cardiovasc Ther. 2017. https://doi.org/10.1111/1755-5922.12285.CrossRefPubMed

79.

Zhou S, Fang X, Xin H, et al. Effects of alendronate on the Notch1-RBP-Jκ signaling pathway in the osteogenic differentiation and mineralization of vascular smooth muscle cells. Mol Med Rep. 2013;8(1):89–94. https://doi.org/10.3892/mmr.2013.1489.CrossRefPubMed

80.

Giollo A, Rossini M, Gatti D, et al. Amino-bisphosphonates and cardiovascular risk: a new hypothesis involving the effects on gamma-delta T cells. J Bone Miner Res. 2019;34(3):570–1. https://doi.org/10.1002/jbmr.3660.CrossRefPubMed

81.

Steinbuch M, D’Agostino RB, Mandel JS, et al. Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regulatory toxicology and pharmacology: RTP. 2002;35(3):320–6. https://doi.org/10.1006/rtph.2002.1550.CrossRefPubMed

82.

Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22. https://doi.org/10.1056/NEJMoa067312.CrossRefPubMed

83.

Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–809. https://doi.org/10.1056/NEJMoa074941.CrossRefPubMed

84.

Reid IR, Horne AM, Mihov B, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;379(25):2407–16. https://doi.org/10.1056/NEJMoa1808082.CrossRefPubMed

85.

Reid IR, Horne AM, Mihov B, et al. Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res. 2020;35(1):20–7. https://doi.org/10.1002/jbmr.3860.CrossRefPubMed

86.

Bunch TJ, Anderson JL, May HT, et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. The American journal of cardiology. 2009;103(6):824–8. https://doi.org/10.1016/j.amjcard.2008.11.037.CrossRefPubMed

87.

Cummings SR, Lui L-Y, Eastell R, et al. Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern Med. 2019. https://doi.org/10.1001/jamainternmed.2019.2779.CrossRefPubMedPubMedCentral

88.

Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118–24. https://doi.org/10.1210/jcem.85.11.6953.CrossRefPubMed

89.

Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168(8):826–31. https://doi.org/10.1001/archinte.168.8.826.CrossRefPubMed

90.

Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (Clin Res ed). 2008;336(7648):813–6. https://doi.org/10.1136/bmj.39507.551644.BE.CrossRef

91.

Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009;265(5):581–92. https://doi.org/10.1111/j.1365-2796.2008.02065.x.CrossRefPubMed

92.

Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65. https://doi.org/10.1056/NEJMoa0809493.CrossRefPubMed

93.

Samelson EJ, Miller PD, Christiansen C, et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res. 2014;29(2):450–7. https://doi.org/10.1002/jbmr.2043.CrossRefPubMedPubMedCentral

94.

Jordan LR, Dallemagne CR, Cross RB. Cardiovascular effects of parathyroid hormone in conscious sheep. Exp Physiol. 1991;76(2):251–7. https://doi.org/10.1113/expphysiol.1991.sp003491.CrossRefPubMed

95.

Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230–40. https://doi.org/10.1016/s0140-6736(17)32137-2.CrossRefPubMed

96.

Nishikawa A, Ishida T, Taketsuna M, et al. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report. Clin Interv Aging. 2016;11:913–25. https://doi.org/10.2147/CIA.S107285.CrossRefPubMedPubMedCentral

97.

Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–33. https://doi.org/10.1001/jama.2016.11136.CrossRefPubMed

98.

Final summary minutes of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting (January 16). Food and Drug Administration, Center for Drug Evaluation and Research. 2019.

99.

Evenity: EPAR public assessment report. European Medicines Agency. 2019.

100.

Cosman F, Crittenden DB, Ferrari S, et al. FRAME Study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res. 2018;33(7):1219–26. https://doi.org/10.1002/jbmr.3427.CrossRefPubMed

101.

Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43. https://doi.org/10.1056/NEJMoa1607948.CrossRefPubMed

102.

Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–27. https://doi.org/10.1056/NEJMoa1708322.CrossRefPubMed

103.

Lv F, Cai X, Yang W, et al. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta- analysis. Bone. 2020;130:115121. https://doi.org/10.1016/j.bone.2019.115121.CrossRefPubMed

104.

Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Guideline update. J Clin Endocrinol Metab. 2020. https://doi.org/10.1210/clinem/dgaa048.CrossRefPubMed

105.

Appelman-Dijkstra NM, Papapoulos SE. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. Nat Rev Endocrinol. 2018;14(10):605–23. https://doi.org/10.1038/s41574-018-0087-0.CrossRefPubMed

106.

Zhu D, Mackenzie NC, Millan JL, et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE. 2011;6(5):e19595. https://doi.org/10.1371/journal.pone.0019595.CrossRefPubMedPubMedCentral

107.

Evenepoel P, Goffin E, Meijers B, et al. Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin Endocrinol Metab. 2015;100(12):4669–76. https://doi.org/10.1210/jc.2015-3056.CrossRefPubMed

108.

Krishna SM, Seto SW, Jose RJ, et al. Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis. Arterioscler Thromb Vasc Biol. 2017;37(3):553–66. https://doi.org/10.1161/atvbaha.116.308723.CrossRefPubMed

109.

Javaheri B, Herbert E, Hopkinson M, et al. Sost haploinsufficiency provokes peracute lethal cardiac tamponade without rescuing the osteopenia in a mouse model of excess glucocorticoids. Am J Pathol. 2019;189(4):753–61. https://doi.org/10.1016/j.ajpath.2018.12.007.CrossRefPubMedPubMedCentral

110.

Kuipers AL, Miljkovic I, Barinas-Mitchell E, et al. Wnt pathway gene expression is associated with arterial stiffness. J Am Heart Assoc. 2020;9(3):e014170. https://doi.org/10.1161/jaha.119.014170.CrossRefPubMedPubMedCentral

111.

Florio M, Gunasekaran K, Stolina M, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016;7:11505. https://doi.org/10.1038/ncomms11505.CrossRefPubMedPubMedCentral

112.

Di M, Wang L, Li M, et al. Dickkopf1 destabilizes atherosclerotic plaques and promotes plaque formation by inducing apoptosis of endothelial cells through activation of ER stress. Cell Death Dis. 2017;8(7):e2917. https://doi.org/10.1038/cddis.2017.277.CrossRefPubMedPubMedCentral

113.

Moe SM, Chen NX, Newman CL, et al. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res. 2015;30(3):499–509. https://doi.org/10.1002/jbmr.2372.CrossRefPubMed

114.

Ominsky MS, Boyd SK, Varela A, et al. Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2017;32(4):788–801. https://doi.org/10.1002/jbmr.3036.CrossRefPubMed

115.

Balemans W, Van Hul W. Identification of the disease-causing gene in sclerosteosis–discovery of a novel bone anabolic target? J Musculoskelet Neuronal Interact. 2004;4(2):139–42.PubMed

116.

van Lierop AH, Appelman-Dijkstra NM, Papapoulos SE. Sclerostin deficiency in humans. Bone. 2017;96:51–62. https://doi.org/10.1016/j.bone.2016.10.010.CrossRefPubMed

117.

Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet. 2003;63(3):192–7. https://doi.org/10.1034/j.1399-0004.2003.00036.x.CrossRefPubMed

118.

Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME Extension study. J Bone Miner Res. 2019;34(3):419–28. https://doi.org/10.1002/jbmr.3622.CrossRefPubMed

119.

Lewiecki EM, Blicharski T, Goemaere S, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183–93. https://doi.org/10.1210/jc.2017-02163.CrossRefPubMed

120.

Cummings SR, McCulloch C. Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab. Osteoporos Int. 2020. https://doi.org/10.1007/s00198-020-05379-z.CrossRefPubMed

121.

Approval of the marketing authorisation for Evenity (romosozumab): re-examination leads to recommendation to approve. 2019.

Title: Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
Authors: N. R. Fuggle
C. Cooper
N. C. Harvey
N. Al-Daghri
M.-L. Brandi
O. Bruyere
A. Cano
E. M. Dennison
A. Diez-Perez
J.-M. Kaufman
S. Palacios
D. Prieto-Alhambra
S. Rozenberg
T. Thomas
F. Tremollieres
R. Rizzoli
J. A. Kanis
J. Y. Reginster
Publication date: 01-10-2020
Publisher: Springer International Publishing
Keywords: Stroke
Bisphosphonate
Myocardial Infarction
Osteoporosis
Osteoporosis
Denosumab
Denosumab
Selective Estrogen Receptor Modulator
Published in: Drugs / Issue 15/2020
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-020-01364-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 15/2020

Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer

Belantamab Mafodotin: First Approval

Correction to: Fostemsavir: First Approval

Atezolizumab: A Review in Extensive-Stage SCLC

Management of Thrombotic Complications in COVID-19: An Update

Bulevirtide: First Approval